Get the Stockscreener App
1.42
2.16%
0.03
After Hours:
1.41
-0.01
-0.70%
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics Restores Nasdaq Listing Compliance - Nasdaq
Lucid Diagnostics regains compliance with Nasdaq listing requirement - MSN
Lucid Diagnostics meets Nasdaq minimum bid price rule By Investing.com - Investing.com South Africa
Lucid Diagnostics meets Nasdaq minimum bid price rule - Investing.com
Lucid Diagnostics Averts Delisting Risk: What This Nasdaq Compliance Means for Investors - StockTitan
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health -February 20, 2025 at 08:31 am EST - Marketscreener.com
Lucid Diagnostics secures concierge medicine contract By Investing.com - Investing.com Nigeria
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics secures concierge medicine contract - Investing.com
Can Lucid's New Concierge Medicine Deal Transform Its Revenue Model? - StockTitan
PAVmed regains compliance with Nasdaq Capital Market’s CLS - Medical Buyer
PAVMPavmed Latest Stock News & Market Updates - StockTitan
Innovative Tech Company Surges Forward: PAVmed Triumphs in Nasdaq Compliance - Smartphone Magazine
Navigating the High Seas of Market Compliance: PAVmed’s Resilient Return - Mi Valle
PAVmed Triumphs on Nasdaq: A Medical Tech Comeback Story - Jomfruland.net
Critical Victory: PAVmed's Strategic Moves Save Nasdaq StatusFull Details Inside - StockTitan
SI-BONE (NASDAQ:SIBN) vs. Lucid Diagnostics (NASDAQ:LUCD) Head to Head Survey - Defense World
Lucid Diagnostics stock hits 52-week high at $1.5 amid growth optimism - MSN
Lucid Diagnostics (NASDAQ:LUCD) vs. Insulet (NASDAQ:PODD) Head-To-Head Review - Defense World
Lucid Diagnostics stock hits 52-week high at $1.5 amid growth optimism By Investing.com - Investing.com South Africa
Lucid Diagnostics Inc (LUCD) receives a Buy rating from Ascendiant Capital Markets - Knox Daily
Behind Lucid Diagnostics Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Lucid Diagnostics Inc (LUCD) Shares Rise Despite Market Challenges - The News Heater
Sargent Investment Group LLC Purchases Shares of 541,500 Lucid Diagnostics Inc. (NASDAQ:LUCD) - MarketBeat
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science and Diagnostic Tools Conference - Marketscreener.com
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Victoria Advocate
Cancer Prevention Leader Lucid Diagnostics Takes Center Stage at Elite BTIG Healthcare Summit - StockTitan
Lucid Diagnostics Provides Business Update and Second Quarter 20 - GuruFocus.com
Lucid Diagnostics (NASDAQ:LUCD) Stock Price Down 0.5%What's Next? - MarketBeat
Lucid Diagnostics (NASDAQ:LUCD) Stock Price Down 0.5% – Here’s What Happened - Defense World
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume - PR Newswire
Lucid Diagnostics Achieves Record-Breaking Quarter with 84% Surge in EsoGuard DNA Test Volume - StockTitan
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - Kilgore News Herald
Lucid Inks New Partnership With VITALExam: Stock to Gain? - MSN
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophag - GuruFocus.com
Lucid Gains Extension of Compliance by NASDAQ - Baystreet.ca
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Quantisnow
Lucid Diagnostics Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Defense World
Lucid Diagnostics Gets Nasdaq Extension to Meet $1 Listing Requirement Through June 2025 - StockTitan
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Eastern Progress Online
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - PR Newswire
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - The Eastern Progress Online
Lucid Diagnostics' SWOT analysis: stock faces challenges amid market potential - Investing.com
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - Morningstar
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire) - Aktiellt
Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $7.00 at Ascendiant Capital Markets - Defense World
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - The Eastern Progress Online
PAVmed Provides Business Update and Third Quarter 2024 Financial Results - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones – Company AnnouncementFT.com - Financial Times
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 30.6% in November - MarketBeat
1.29%
2.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):